Rani Therapeutics Holdings, Inc. (RANI)

6.31 -0.47 (-6.93%) 收市：04:00PM EDT

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 140

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Mir A. Imran	Executive Chairman	80k	無	1957
Mr. Talat Imran	CEO & Director	450k	無	1982
Mr. Svai S. Sanford	Chief Financial Officer	416k	無	1970
Dr. Mir Hashim	Chief Scientific Officer	416k	無	1960
Mr. Eric Groen	General Counsel	無	無	1971
Ms. Bella Vazquez	Vice President of Human Resources	無	無	無
Ms. Kate McKinley M.B.A.	Chief Business Officer	無	無	1977
Ms. Arvinder Dhalla	Vice President of Clinical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

公司管治

截至 無 止，Rani Therapeutics Holdings, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。